DBV Technologies | DBVT - Pre Tax Profit


DBV Technologies reported $-47.4M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 46.47M 42.49M Jun/2026
Alnylam Pharmaceuticals USD 177.81M 43.85M Jun/2026
Amarin USD -852K 7.26M Dec/2025
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
DBV Technologies USD -47.4M 14.24M Mar/2026
Galectin Therapeutics USD -12.37M 880K Jun/2024
Halozyme Therapeutics USD 180.33M 281.18M Mar/2026
Incyte USD 751.51M 407.91M Jun/2026
Insmed USD -11.37M 150.72M Jun/2026
Ionis Pharmaceuticals USD -114M 21M Jun/2026
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Sarepta Therapeutics USD -1.75M 344.92M Jun/2026
Ultragenyx Pharmaceutical USD -91M 93M Jun/2026
United Therapeutics USD 372.7M 54.4M Jun/2026